SDGR (Schrodinger, Inc.) — AI Stock Analysis & Recommendation

Research of October 13, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate SDGR a HOLD. The latest price is $25.89.

The research plan

• Entry: $25.89
• Time horizon: days

The current setup does not warrant a BUY, necessitating a HOLD to await further clarity.

Why

While SDGR exhibits potential in AI drug discovery, the neutral market regime, coupled with a neutral technical verdict and significant valuation concerns, prevents a BUY recommendation. The high risk score and lack of strong bullish conviction across all teams necessitate a HOLD.

What could push SDGR higher

• Continued advancements in AI drug discovery capabilities.
• Strategic partnerships that could accelerate pipeline development.
• Potential for positive clinical trial data for drug candidates.

Key risks for SDGR

• Persistent unprofitability and significant cash burn.
• Overvaluation concerns despite fundamental potential.
• High volatility and beta, increasing downside risk.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

Schrödinger's strong technological moat and hybrid business model offer long-term potential, but current unprofitability, decelerating growth, and insider selling create near-term headwinds. The speculative valuation is justified by its niche leadership and drug discovery upside, but requires careful monitoring of cash burn and progress towards profitability.

• Schrödinger operates a hybrid business model with recurring software revenue and high-margin drug discovery potential, supported by strong gross margins.
• The company is consistently unprofitable with negative net income and operating margins, and a significant cash burn despite a substantial cash position.
• Revenue growth is positive but decelerating, and the current stock price is above the mean analyst target, suggesting limited immediate upside based on consensus.

Technical team: Neutral

The stock is in a short-term uptrend but is currently facing significant resistance at $29.18, coupled with bearish momentum signals and subdued volume. The price is consolidating near the $25.53 support, suggesting a neutral outlook with potential for a short-term pullback before any sustained directional move.

• The stock is in a short-term and medium-term uptrend, trading above MA20 and MA50, but is currently facing resistance at $29.18 with a bearish reversal candle, suggesting a potential pullback to $25.53.
• Trading activity is subdued with volume generally below the 20-day MA, indicating consolidation. A prior volume spike suggests buying interest, but recent mixed volume and slight downtrend from highs are inconclusive.
• Momentum indicators (MACD, Stochastic) are showing bearish signals, with RSI around 45 indicating neutrality. Price is consolidating near support S3 at $25.53.

Sentiment team: Neutral

Schrödinger's sentiment is currently neutral, balancing promising AI advancements and strategic partnerships against significant concerns about overvaluation, insider selling, and near-term financial performance. While the AI catalyst is a positive driver, the persistent valuation and profitability issues create a balanced outlook, preventing a clear bullish or bearish verdict.

• Schrödinger's news sentiment is neutral, characterized by significant advancements in AI drug discovery and strategic partnerships, but tempered by persistent concerns over stock overvaluation, insider selling, and challenges in its business model...
• Schrödinger (SDGR) exhibits a neutral sentiment, characterized by a split between analyst optimism and AI-driven overvaluation concerns, alongside subdued retail investor discussion and notable insider selling. (Score: 0.01)
• Schrödinger (SDGR) exhibits a neutral sentiment due to a mix of positive analyst recommendations and price target potential, offset by concerns regarding overvaluation, insider selling, and recent revenue performance.

Risk team: High

SDGR presents a high-risk profile due to its extreme volatility, significant historical drawdowns, and ongoing negative cash flow, compounded by the inherent binary risks of its drug discovery business. The high short interest adds another layer of potential volatility, necessitating a very cautious approach.

• High Beta and Realized Volatility: SDGR exhibits high beta (1.65-1.99) and exceptionally high realized volatility (annualized 117.6%), indicating significantly amplified price swings and market sensitivity.
• Deep Historical Drawdown and Negative Cash Flow: The stock has experienced a severe -80% drawdown historically, coupled with consistent negative operating and free cash flow, highlighting significant financial strain and potential for further substantial losses.
• Business Model Complexity and Execution Risk: Schrödinger's hybrid software and drug discovery model presents inherent valuation complexity and requires dual execution excellence, with the success of its capital-intensive drug discovery programs posing a...

SDGR at a glance

Market value	$2.0B
Revenue growth (year over year)	8.9%
Profit margin	-21.0%
Debt / equity	0.00

Every AI call on SDGR since May 7, 2026, and what happened next (8 calls) →

Research of October 13, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.